Adicet Bio, Inc. (ACET), a company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, said on Wednesday that it has appointed Julie Maltzman as Chief Medical Officer with effect from January 13, 2025.
She will succeed Francesco Galimi, who has completed his tenure at Adicet this month.
Maltzman joins Adicet from IconOVir Bio, where she served as Chief Medical Officer.
Earlier, she worked as the VP, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.